Blood Product Usage in Liver Transplantation

2018 ◽  
pp. 161-167
Author(s):  
Deepti Sachan
Keyword(s):  
Liver Transplantation ◽  
Blood Product ◽  
Product Usage

REDUCED BLOOD PRODUCT USAGE WITH TRANEXAMIC ACID PROPHYLAXIS IN PRIMARY LIVER TRANSPLANTATION

1992 ◽  
Vol 77 (Supplement) ◽  
pp. A1092 ◽  
Author(s):  
J F Boylan ◽  
A N Sandler ◽  
P Sheiner ◽  
G OʼLeary ◽  
H Nlerenberg ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Tranexamic Acid ◽  
Blood Product ◽  
Product Usage

THROMBELASTOGRAPHIC AND LABORATORY FINDINGS AS PREDICTORS OF BLOOD PRODUCT USAGE DURING LIVER TRANSPLANTATION

1989 ◽  
Vol 71 (Supplement) ◽  
pp. A416 ◽  
Author(s):  
M. R. Brown ◽  
A. W. Paulsen ◽  
J. Dirting ◽  
F. Takaoka ◽  
M. A.E. Ramsay
Keyword(s):  
Liver Transplantation ◽  
Blood Product ◽  
Laboratory Findings ◽  
Product Usage

DO PREOPERATIVE DIAGNOSIS AND/OR PREOPERATIVE COAGULATION PARAMETERS CORRELATE WITH BLOOD AND BLOOD PRODUCT USAGE DURING ORTHOTOPIC LIVER TRANSPLANTATION?

1996 ◽  
Vol 89 (Supplement) ◽  
pp. S12
Author(s):  
Melinda K. Bailey ◽  
Susan C. Harvey ◽  
Gary R. Haynes ◽  
Frank J. Overdyk ◽  
Joanne M. Conroy ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Orthotopic Liver Transplantation ◽  
Preoperative Diagnosis ◽  
Blood Product ◽  
Product Usage ◽  
Coagulation Parameters

scholarly journals The Impact of Thromboelastography on Decreasing Blood Product Usage in Liver Transplantation

2021 ◽  
Vol 233 (5) ◽  
pp. e201
Author(s):  
Adhnan Mohamed ◽  
Toshihiro Kitajima ◽  
Tayseer Shamaa ◽  
Ahmed M. Elsabbagh ◽  
Atsushi Yoshida ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Blood Product ◽  
Product Usage ◽  
The Impact

226Low blood product requirements in a liver transplantation program

2000 ◽  
Vol 6 (3) ◽  
pp. C56-C56
Author(s):  
P CHAPCHAP ◽  
E CARONE ◽  
V PUGLIESE ◽  
S BIAGINI ◽  
E SILVA ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Blood Product ◽  
Transplantation Program

Aprotinin Versus Tranexamic Acid During Liver Transplantation: Impact on Blood Product Requirements and Survival

2011 ◽  
Vol 91 (11) ◽  
pp. 1273-1278 ◽  
Author(s):  
Luc Massicotte ◽  
André Y. Denault ◽  
Danielle Beaulieu ◽  
Lynda Thibeault ◽  
Zoltan Hevesi ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Tranexamic Acid ◽  
Blood Product

Temporal changes in blood product usage in preterm neonates born at less than 30 weeks' gestation in Canada

Transfusion ◽  
2015 ◽  
Vol 55 (6) ◽  
pp. 1340-1346 ◽  
Author(s):  
Amy K. Keir ◽  
Junmin Yang ◽  
Adele Harrison ◽  
Ermelinda Pelausa ◽  
Prakesh S. Shah ◽  
...  
Keyword(s):  
Blood Product ◽  
Temporal Changes ◽  
Preterm Neonates ◽  
Product Usage

scholarly journals Geographic differences in hemophilia-associated AIDS incidence in Pennsylvania. By the Pennsylvania AIDS Surveillance Study Group

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1208-1210 ◽  
Keyword(s):  
Blood Product ◽  
Fresh Frozen Plasma ◽  
Factor Ix ◽  
Antibody Prevalence ◽  
Product Usage ◽  
Fresh Frozen ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Hemophilia Treatment Centers ◽  
Frozen Plasma

A 1986 survey of seven hemophilia treatment centers in Pennsylvania (PA) has revealed that 22 hemophiliacs residing in PA have developed the acquired immunodeficiency syndrome (AIDS), representing 9.2% of the total 238 United States hemophiliac AIDS cases. These 22 included ten (45.5%) from western PA (W-PA), eleven (50.0%) from central PA (C-PA), and one (0.5%) from eastern PA (E-PA). The HIV antibody prevalence for these three geographic groups is comparable, with 84 of 178 (47.2%) of hemophiliacs in W-PA seropositive, 102 of 182 (56.0%) in C-PA seropositive, and 105 of 177 (59.3%) in E-PA seropositive. Blood product usage for these three areas is comparable: 47.8 X 10(3) (W-PA) v 43.9 (C-PA) v 53.3 (E-PA) units factor VIII concentrate per patient per year; 36.5 v 24.5 v 33.7 for factor IX concentrate; 8.4 v 4.7 v 7.7 for cryoprecipitate; and 1.3 v 2.7 v 1.0 for fresh frozen plasma, respectively. These data demonstrate a geographic variation in hemophilia AIDS incidence in PA, with a tenfold higher incidence in W- PA and C-PA than E-PA, which is unrelated to differences in HIV antibody prevalence, patient blood product usage, or inaccuracies in AIDS case reporting. Because of the greater than or equal to 5 year median latency between HIV infection and development of AIDS, the AIDS incidence will continue to change, but other factors appear to be operative in the development of AIDS in hemophiliacs.

Blood-product usage in cardiac surgery

1989 ◽  
Vol 3 (6) ◽  
pp. 776-784 ◽  
Author(s):  
Joan Uehlinger ◽  
Louis M. Aledort
Keyword(s):  
Cardiac Surgery ◽  
Blood Product ◽  
Product Usage

scholarly journals Geographic differences in hemophilia-associated AIDS incidence in Pennsylvania. By the Pennsylvania AIDS Surveillance Study Group

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1208-1210 ◽  
Keyword(s):  
Blood Product ◽  
Fresh Frozen Plasma ◽  
Factor Ix ◽  
Antibody Prevalence ◽  
Product Usage ◽  
Fresh Frozen ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Hemophilia Treatment Centers ◽  
Frozen Plasma

Abstract A 1986 survey of seven hemophilia treatment centers in Pennsylvania (PA) has revealed that 22 hemophiliacs residing in PA have developed the acquired immunodeficiency syndrome (AIDS), representing 9.2% of the total 238 United States hemophiliac AIDS cases. These 22 included ten (45.5%) from western PA (W-PA), eleven (50.0%) from central PA (C-PA), and one (0.5%) from eastern PA (E-PA). The HIV antibody prevalence for these three geographic groups is comparable, with 84 of 178 (47.2%) of hemophiliacs in W-PA seropositive, 102 of 182 (56.0%) in C-PA seropositive, and 105 of 177 (59.3%) in E-PA seropositive. Blood product usage for these three areas is comparable: 47.8 X 10(3) (W-PA) v 43.9 (C-PA) v 53.3 (E-PA) units factor VIII concentrate per patient per year; 36.5 v 24.5 v 33.7 for factor IX concentrate; 8.4 v 4.7 v 7.7 for cryoprecipitate; and 1.3 v 2.7 v 1.0 for fresh frozen plasma, respectively. These data demonstrate a geographic variation in hemophilia AIDS incidence in PA, with a tenfold higher incidence in W- PA and C-PA than E-PA, which is unrelated to differences in HIV antibody prevalence, patient blood product usage, or inaccuracies in AIDS case reporting. Because of the greater than or equal to 5 year median latency between HIV infection and development of AIDS, the AIDS incidence will continue to change, but other factors appear to be operative in the development of AIDS in hemophiliacs.

Sign in / Sign up

Export Citation Format

Share Document